Can you take Lepirudin with Prasugrel?
1 drug interaction and 13 additional warnings found for the following 2 drugs:
- lepirudin
- prasugrel
Drug interactions
Major drug interactions
Major:
lepirudin prasugrel
Applies to: lepirudin and prasugrel
Using prasugrel together with lepirudin may increase the risk of bleeding, including severe and sometimes fatal hemorrhage.
Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.
You should seek immediate medical attention if you experience any unusual bleeding or bruising, or have other signs and symptoms of bleeding such as:
- dizziness
- lightheadedness
- red or black, tarry stools
- coughing up or vomiting fresh or dried blood that looks like coffee grounds
- severe headache
- weakness
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
13 potential interactions Applies to: 11 conditions, including High Blood Pressure, Peptic Ulcer, Liver Disease, Bleeding Disorder, and Diabetic Retinopathy.
Bleeding Disorder
Major:
prasugrel
Prasugrel has a major potential interaction with Bleeding Disorder.
Prasugrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage, as this agent increases the risk of fatal bleeding.
Cerebrovascular Insufficiency
Major:
prasugrel
Prasugrel has a major potential interaction with Cerebrovascular Insufficiency.
Prasugrel is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke. Patients who experience a stroke or TIA while on prasugrel generally should have therapy discontinued. The risk of bleeding is increased in patients receiving prasugrel who undergo coronary artery bypass graft. If possible, prasugrel should be discontinued at least 7 days prior to the procedure.
Coagulation Defects and Disorders
Major:
lepirudin
Lepirudin has a major potential interaction with Coagulation Defects and Disorders.
Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies. The risk of hemorrhage may be increased in these patients.
Diabetic Retinopathy
Major:
lepirudin
Lepirudin has a major potential interaction with Diabetic Retinopathy.
The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy. Therapy with anticoagulants should be administered with extreme caution in such patients.
High Blood Pressure
Moderate:
lepirudin
Lepirudin has a moderate potential interaction with High Blood Pressure.
Anticoagulants should be used with extreme caution in patients at increased risk for hemorrhage, including those patients with severe hypertension.
Hypertensive Retinopathy
Major:
lepirudin
Lepirudin has a major potential interaction with Hypertensive Retinopathy.
The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy. Therapy with anticoagulants should be administered with extreme caution in such patients.
Infectious Endocarditis
Major:
lepirudin
Lepirudin has a major potential interaction with Infectious Endocarditis.
Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis. The risk of hemorrhage may be increased in these patients.
Ischemic Heart Disease
Major:
prasugrel
Prasugrel has a major potential interaction with Ischemic Heart Disease.
Prasugrel is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke. Patients who experience a stroke or TIA while on prasugrel generally should have therapy discontinued. The risk of bleeding is increased in patients receiving prasugrel who undergo coronary artery bypass graft. If possible, prasugrel should be discontinued at least 7 days prior to the procedure.
Liver Disease
Major:
lepirudin
Lepirudin has a major potential interaction with Liver Disease.
Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.
Moderate:
prasugrel
Prasugrel has a moderate potential interaction with Liver Disease.
No dosage adjustment is necessary for patients with renal impairment. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. Caution should be exercised in patients with end-stage renal disease and those with severe hepatic disease as such patients are generally at higher risk of bleeding.
Peptic Ulcer
Major:
lepirudin
Lepirudin has a major potential interaction with Peptic Ulcer.
Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage. Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%. However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.
Renal Dysfunction
Moderate:
lepirudin
Lepirudin has a moderate potential interaction with Renal Dysfunction.
Anticoagulants should be given with extreme caution to patients with severe kidney dysfunction. Altered coagulation may increase the risk of bleeding in these patients. If an anticoagulant is administered, these patients should be monitored closely for signs of bleeding.
Moderate:
prasugrel
Prasugrel has a moderate potential interaction with Renal Dysfunction.
No dosage adjustment is necessary for patients with renal impairment. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. Caution should be exercised in patients with end-stage renal disease and those with severe hepatic disease as such patients are generally at higher risk of bleeding.
Report options
More resources
lepirudin
A total of 166 drugs are known to interact with lepirudin.
- Lepirudin is in the drug class thrombin inhibitors.
- Lepirudin is used to treat Thrombocytopenia Drug Induced.
prasugrel
A total of 234 drugs are known to interact with prasugrel.
- Prasugrel is in the drug class platelet aggregation inhibitors.
- Prasugrel is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.